An interventional study of Self-compassion intervention (the Mindful Self-Compassion course) in Multiple Sclerosis and Self-Compassion, sponsored by Robert Simpson. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-06.
Sponsored by Robert Simpson · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 257 studies in Multiple Sclerosis with a site in Canada — 25 open to participants now, 43 under way, 12 of them phase 3. Multiple Sclerosis · Canada.
Among the 257 studies in Multiple Sclerosis with a site in Canada, this one is the 163rd largest by planned enrollment of the 215 interventional ones that give a count, is one of 11 that started in 2025, is one of 53 with no phase, reaches primary completion later than 9 of the 42 other live ones, and was the 242nd registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →25 of the 257 studies in Multiple Sclerosis with a site in Canada are open now. Recruiting first, the newest first:
Kite, A Gilead Company · Sites in Canada, United States, Australia
Ages 18–75
University Health Network, Toronto · Sites in Canada
Ages 18–65
AstraZeneca · Sites in Canada, United States, Australia and 2 more countries
Ages 18–60
University of Calgary · Sites in Canada
Ages 26–59
Novartis Pharmaceuticals · Sites in Canada, United States, Argentina and 33 more countries
Ages 18–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
257 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 60 · Phase 3 85 · Phase 4 13
First in 2001; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is close to the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 177 across the 215 interventional studies, 172 across the 42 observational. Of the 200 that completed or were terminated, 97 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 257 have an industry lead sponsor. The 10 most frequent:
Robert Simpson is the lead sponsor of 5 studies on the registry; 5 are open to participants now.
Robert Simpson has 3 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
12 of the studies in Multiple Sclerosis with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT06415552Robert SimpsonImplementation of Online Mindfulness-Based Stress Reduction Tailored for People with Multiple Sclerosis | 2026-12-31 |
| NCT04121468The Hospital for Sick ChildrenA Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis | 2027-03 |
| NCT05090371Novartis PharmaceuticalsA Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation | 2027-04-13 |
| NCT06782490CelgeneA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | 2027-05-26 |
Add all 12 to your calendar (.ics) → With an account.
Among the 257 studies in Multiple Sclerosis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to develop and investigate a compassion-based intervention (Mindful Self-Compassion course) in people with multiple sclerosis. The main objectives are:
Participants will be asked to take part in an 8-week online Mindful Self-Compassion course and report changes in levels of stress, anxiety, depression, self-compassion, adjustment, emotion, and quality of life from pre- to post-intervention and at 3-month follow-up. Additionally, participants will be asked to take part in a semi-structured interview to explore their experiences with the course, perceived effects, and suggestions for improvement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
8-week manualized online Mindful Self-Compassion course
Behavioral: Self-compassion intervention (the Mindful Self-Compassion course)
An online 8-week mindful self-compassion course with weekly sessions.
Recruitment
The investigators will measure the number of participants eligible for and recruited to the study.
Time frame: 4 months
Retention
The investigators will measure the percentage of participants who complete outcome data.
Time frame: 4 months
Adherence
The investigators will measure the number of participants who completed the mindful self-compassion course.
Time frame: 4 months
Follow-up rates
The investigators will measure the percentage of participants who complete outcome measures pre-intervention, post-intervention, and at 3 months post-intervention.
Time frame: 4 months
Stress
Measured using the Perceived Stress Scale-10. The total score can range from 0-40, with higher scores indicating higher perceived stress.
Time frame: Measured at baseline, 8-week follow-up, and 3-month follow-up.
Anxiety
Measured using the Hospital Anxiety and Depression Scale. The total score ranges from 0-21, with higher values representing increased anxiety symptoms.
Time frame: Measured at baseline, 8-week follow-up, and 3-month follow-up.
Depression
Measured using the Hospital Anxiety and Depression Scale. The total score ranges from 0-21, with higher values representing increased depressive symptoms.
Time frame: Measured at baseline, 8-week follow-up, and 3-month follow-up.
Self-compassion
Measured using the Self-Compassion Scale - Short Form. The total score ranges from a 1-5 Likert scale, with higher scores representing high self-compassion.
Time frame: Measured at baseline, 8-week follow-up, and 3-month follow-up.
Emotion Regulation
Measured using the Difficulties in Emotion Regulation Scale - Short Form. Answers are assessed using a 5-point Likert scale. Higher values indicate greater difficulties in emotion regulation.
Time frame: Measured at baseline, 8-week follow-up, and 3-month follow-up.
Quality of Life using the Multiple Sclerosis Impact Scale (MSIS-29)
Measured using the Multiple Sclerosis Impact Scale. Items on the scale have a Likert scale from 1-5, with a range of 0-100 total and higher scores indicating greater disability.
Time frame: Measured at baseline, 8-week follow-up, and 3-month follow-up.
Participant Experiences and Perspectives
Semi-structured interviews will aim to capture participants' experiences with the course and perspectives on the use of self-compassion in care.
Time frame: Measured at baseline, 8-week follow-up, and 3-month follow-up.
Adjustment
Measured using the Coping with MS Scale. Answers are assessed using a 5-point Likert scale and a mean per subscale group will be reported. Higher values indicate greater tendency to use coping strategies.
Time frame: Measured at baseline, 8-week follow-up, and 3-month follow-up.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2025; primary completion for Apr 2025, 3 months later.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 3 months is below that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Robert Simpson